ArticleMicrophysiological systems2020
Body-in-a-Cube: a microphysiological system for multi-tissue co-culture with near-physiological amounts of blood surrogate.
Article in Microphysiological systems, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Versatile Microfluidic System for Creating Recirculating Unidirectional Flow for On-Chip Cultures of Barrier Tissues.Bioengineering (Basel, Switzerland) · 2026Article
- Advances and applications of organ-on-a-chip technology.Cell reports methods · 2026Review
- Closed, pumpless microphysiological system with unidirectional flow for co-culture and focal irradiation.RSC advances · 2026Article
- Prostate Cancer-Associated Fibroblasts: A Review on CAF Functions, Heterogeneity, Resistance Mechanisms, and Future in a Chip.International journal of molecular sciences · 2026Review
- Advanced 3D In Vitro Liver Fibrosis Models: Spheroids, Organoids, and Liver-on-Chips.Biomimetics (Basel, Switzerland) · 2025Review
- Open-source tubing-free impeller pump platform for controlled recirculating fluid flow for microfluidics and organs-on-chip.HardwareX · 2025Article
- A 3D-printed multi-compartment organ-on-chip platform with a tubing-free pump models communication with the lymph node.Lab on a chip · 2025Article
- Barrier-free, open-top microfluidic chip for generating two distinct, interconnected 3D microvascular networks.Scientific reports · 2024Article
- Grand challenges in organoid and organ-on-a-chip technologies.Frontiers in bioengineering and biotechnology · 2024Article
- Heart and kidney organoids maintain organ-specific function in a microfluidic system.Materials today. Bio · 2023Article
- Nanostructured N, S, and P-Doped Elaeagnus Angustifolia Gum-Derived Porous Carbon with Electrodeposited Silver for Enhanced Electrochemical Sensing of Acetaminophen.Nanomaterials (Basel, Switzerland) · 2023Article
- Novel Quick Cell Patterning Using Light-Responsive Gas-Generating Polymer and Fluorescence Microscope.Micromachines · 2022Article
- Review
- Critical Considerations for the Design of Multi-Organ Microphysiological Systems (MPS).Frontiers in cell and developmental biology · 2021Review
- Translational Roadmap for the Organs-on-a-Chip Industry toward Broad Adoption.Bioengineering (Basel, Switzerland) · 2020Review
- Pumped and pumpless microphysiological systems to study (nano)therapeutics.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundDecreasing the amount of liquid inside microphysiological systems (MPS) can help uncover the presence of toxic drug metabolites. However, maintaining near-physiological volume ratios among blood surrogate and multiple organ mimics is technically challenging. Here, we developed a body cube and tested its ability to support four human tissues (kidney, GI tract, liver, and bone marrow) scaled down from in vivo functional volumes by a factor of 73,000 with 80 μL of cell culture medium (corresponding to ~1/73000th of in vivo blood volume).
methodsGI tract cells (Caco-2), liver cells (HepG2/C3A), bone marrow cells (Meg-01), and kidney cells (HK-2) were co-cultured inside the body cube with 80 μL of common, recirculating cell culture medium for 72 h. The system was challenged with acetaminophen and troglitazone, and concentrations of aspartate aminotransferase (AST), albumin, and urea were monitored over time.
resultsCell viability analysis showed that 95.5%±3.2% of liver cells, 89.8%±4.7% of bone marrow cells, 82.8%±8.1% of GI tract cells, and 80.1%±11.5% of kidney cells were viable in co-culture for 72 h. Both acetaminophen and troglitazone significantly lowered cell viability in the liver chamber as indicated by viability analysis and a temporary increase of AST in the cell culture medium. Both drugs also lowered urea production in the liver by up to 45%.
conclusionsCell viability data and the production of urea and albumin indicate that the co-culture of GI tract, liver, bone marrow, and kidney tissues with near-physiological volume ratios of tissues to blood surrogate is possible for up to 72 h. The body-cube was capable of reproducing liver toxicity to HepG2/C3A liver cells via acetaminophen and troglitazone. The developed design provides a viable format for acute toxicity testing with near-physiological blood surrogate to tissue volume ratios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.